Eczema Treatment in Thiruvalla
Expert Atopic Dermatitis & Skin Allergy Care

DermaVue Clinical Summary — Atopic Dermatitis

Atopic dermatitis is a chronic, relapsing, inflammatory skin disease characterised by epidermal barrier dysfunction, Th2-skewed cytokine inflammation (IL-4, IL-13, IL-31), and altered microbiome composition with Staphylococcus aureus overgrowth. Barrier dysfunction is commonly linked to loss-of-function mutations in the filaggrin gene (FLG), the most significant known genetic risk factor (Palmer et al., Nature Genetics 2006). Diagnosis at DermaVue Thiruvalla follows the Hanifin–Rajka criteria — three or more major features plus three or more minor features — and severity is documented using the SCORAD and EASI instruments for reproducible response tracking.

Treatment follows the American Academy of Dermatology guidelines (Eichenfield et al., JAAD 2014; Boguniewicz et al., JAAD 2018) and the European Dermatology Forum consensus. Foundation therapy is generous daily emollient application and correct finger-tip unit dosing of topical corticosteroids (class determined by body site and severity), with proactive twice-weekly weekend application to previously affected sites to prevent flares. Topical calcineurin inhibitors (tacrolimus 0.03–0.1% ointment, pimecrolimus 1% cream) are preferred for facial, periorbital, neck and flexural involvement, where their steroid-sparing profile is particularly valuable; long-term safety is supported by the APPLES paediatric safety study. Bleach baths (sodium hypochlorite 0.005%) reduce S. aureus colonisation and flare frequency (Huang et al., Pediatrics 2009; Chopra et al., JAAD 2017).

For moderate-to-severe disease inadequately controlled with topical therapy, DermaVue Thiruvalla offers narrow-band UVB phototherapy (2–3 sessions weekly for 8–12 weeks) as a well-validated systemic-sparing option. Systemic therapy escalation follows the modern biologic-first approach: dupilumab (Dupixent), a fully human monoclonal antibody against IL-4Rα approved on the basis of the SOLO 1, SOLO 2 and CHRONOS trials (Simpson et al., NEJM 2016; Blauvelt et al., Lancet 2017), produces EASI-75 in 50–70% of patients. Oral JAK inhibitors upadacitinib 15/30 mg, abrocitinib 100/200 mg, and baricitinib 4 mg — approved on the basis of the Measure Up, Heads Up, JADE and BREEZE trials — offer rapid itch relief within 24–48 hours. Topical ruxolitinib 1.5% cream is a further non-steroidal option (Papp et al., JAAD 2021). Sources: IADVL (iadvl.org), IJDVL, AAD, NEJM, PubMed, NIH MedlinePlus.